First participant dosed in Ionis’ Phase I-II ASCEND study
The open-label trial enrolled patients aged between two and 12 years who have a clinical diagnosis of Dravet syndrome.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance